ImmunityBio, Inc. (IBRX) expected to triple due to potential growth opportunities and revenue increase.

From Yahoo Finance: 2025-04-09 09:42:00

ImmunityBio, Inc. (IBRX) is featured among the 10 Stocks Under $10 that Will Triple. Small-cap stocks have faced challenges due to economic uncertainties and higher interest rates, impacting their performance. However, with potential benefits from Trump’s economic growth agenda and stabilizing inflation, analysts expect a recovery in the second half of 2025. Trade tensions and rising costs from tariffs have added to small-cap stocks’ volatility, affecting profitability. The recovery in mergers and acquisitions (M&A) and initial public offerings (IPOs) could benefit small-caps, offering growth opportunities. Despite market challenges, some small-cap stocks under $10 have shown resilience and growth potential, outperforming the broader market in certain conditions. ImmunityBio, Inc. (IBRX) is a clinical-stage biotech company developing immune-enhancing therapies for cancer and infectious diseases, with a revenue increase and improved financial health in recent quarters. Regulatory approvals and production scalability position IBRX for strong growth potential, making it one of the stocks under $10 that will triple. AI stocks are also seen as promising for higher returns within a shorter timeframe, with potential opportunities for investors.



Read more at Yahoo Finance: Among Stocks Under $10 that Will Triple